XBI
State Street SPDR S&P Biotech ETF
Related News
SEC Filings
Screening
Compare
Economic Calendar
We use cookies in accordance with European GDPR standards to improve site usability, analytics, and deliver personalized advertising.Learn moreCookie Settings
State Street SPDR S&P Biotech ETF (XBI) is rated Buy, with 8%-14% total return expected over 6-12 months despite a 76% prior-year rally. XBI's modified equal-weight structure offers broad exposure to
